NFT Marketplace IOGINALITY Launches, Offering Comprehensive Infrastructure for Digital Art and Bringing Emerging Galleries into the Web3 Fold
22.5.2023 17:33:00 EEST | Business Wire | Press release
IOGINALITY, the first art NFT platform aimed at emerging galleries, today announced its launch to allow galleries and collectors a seamless and fully compliant platform to transact and benefit from the potential of tokenised art.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230522005427/en/
IOGINALITY’s interface (Graphic: Business Wire)
Providing emerging galleries with equitable access to resources
With a target of becoming the go-to platform for art market stakeholders worldwide, IOGINALITY’s initial focus is on bringing legal and technical support and resources to young galleries transitioning to the Web3 world, by offering an ecosystem solution and proven legal structure to accelerate new market entrants globally.
IOGINALITY exclusively permits galleries to mint NFTs, guaranteeing that customers deal only with compliant sellers and verified art. In the same vein, IOGINALITY also provides access to trusted buyers by using automated Know-Your-Customer and Know-Your-Business checks, to allow galleries to connect with collectors confidently and provide a trustworthy solution for the financial and legal security of customers’ deals, in line with the ever-evolving regulatory landscape across jurisdictions.
Simplified fee structure for all stakeholders
Powered by smart contracts, IOGINALITY facilitates instantaneous and straightforward transactions for galleries, artists, and art dealers. At the moment of minting, the NFTs’ selling prices and royalties are immediately aligned across all stakeholders, circumventing the costs, obscurities, and delays that often impede innovation. More importantly, the IOGINALITY platform offers the possibility of appointing an unlimited number of receivers involved in the transaction.
Formed under a partnership with Midas Investments, a major international crypto fund based in Hong Kong, IOGINALITY is co-founded by internationally-renowned lawyers Ekaterina Smirnova, and Yuriy Brisov. Together, they bring extensive experience in digital markets, delivering legal, economic and strategic consulting services, as well as a critical awareness of crypto, NFT and securities regulations.
Commenting on the launch, Ekaterina Smirnova, Founder and CEO, said: “IOGINALITY was established as a direct remedy to the common issues facing the NFT market surrounding a lack of transparency, susceptibility to fraud and laundering as well as equitable access to forward-looking legal support resources. As hype around NFTs fades and the professionals remain, the industry is ripe for fundamental transformation. Emerging galleries are repeatedly expressing a keen desire to embrace Web3 and it is important that the industry creates the necessary hand railings to enable their adoption, while setting the standard for accessibility, professionalism, security and trust. IOGINALITY addresses this by levelling the playing field to allow more galleries to join the digital revolution, ushering in a new world order characterised by greater representation.”
Participation from global emerging galleries
At launch, IOGINALITY will first feature collections from Alisa Gallery, a contemporary art gallery in Dubai, imnotART, Chicago’s first NFT art gallery, as well as Web3 creative studio, Wizara. These partnerships allow IOGINALITY to accelerate the market entry of galleries globally, as part of its core mission to enrich an asymmetrical and closed world with quality digital art from all corners of the world. This global presence will be further facilitated by IOGINALITY’s growing network of NFT art ambassadors, who will drive new partnerships between art institutions, brands, and advertisers.
Adham Hafez, Co-founder, Creative Director, and Curator of Wizara added: “As a theorist and a curator, I have been interested in the fact that many legal scholars have moved to study Web3 and engage with how its potentials will radically not only change our understanding of art, but of society and how it manifests itself legally, artistically, politically, and culturally in general. Wizara sees in IOGINALITY a perfect partner in how it straddles an interest in practice as well as in theory, the way it equally invests in not only supporting artists to break through the market, but equally to assist them in understanding the contractual and legal matters of a world governed by Smart-contracts and blockchain-based agreements that will redefine art economy, and many of the gallerist-artists relations in our art worlds today.”
In line with its public launch, IOGINALITY has also launched an open source page ‘NFT Nightmares: Lessons Learned’. Hosted on the IOGINALITY website, the page features key takeaways from high-profile cases of Web3 fraud and malpractice including the stealing of Banksy’s Morons in 2021, and the infamous Hermes vs Rothschld lawsuit, which have deterred many collectors and galleries from exploring this realm. Open for all to participate in and submit personal experiences to feature in the case library, IOGINALITY’s comprehensive platform serves to contribute to the development and betterment of the Web3 community by increasing transparency and awareness of potential pitfalls.
In the long-term, IOGINALITY intends to expand its project and leverage its cross-industry expertise across art, culture, finance, technology, law and project management to implement NFT solutions across markets covering assets such as gems, collectible wines and real estate.
ENDS
About IOGINALITY
IOGINALITY is a digital art marketplace that combines the convenience of the Web3 world with the safety of art dealerships from top galleries and curators to allow artists, institutions, and collectors to transact and benefit from the potential of tokenised art on an accessible, seamless, and fully compliant platform. Through its focus on professionalism and artistic value, IOGINALITY’s platform serves to provide an ecosystem solution to industry concerns around legal, financial and technological facets.
Designed to facilitate greater representation of emerging galleries, IOGINALITY is reimagining the NFT art sector to become the go-to platform for art institutions and stakeholders worldwide to launch digital exhibitions and create NFT collections.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230522005427/en/
Contact information
For Media Enquiries
Wachsman
Zuhaili Marican
E: ioginality@wachsman.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom